Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

Molecular Pharmacology

Volumn 46, Issue 4, 1994, Pages 594-598

  De Morais, Sonia M F ^a   Wilkinson, Grant R ^b   Blaisdell, Joyce ^a   Meyer, Urs A ^c   Nakamura, Koichi ^d   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF BASEL   (Switzerland)

^d OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; CITALOPRAM; DIAZEPAM; GUANINE; HYDANTOIN DERIVATIVE; MEPHENYTOIN; OMEPRAZOLE; PROGUANIL; PROPRANOLOL;

ALLELE; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BASE PAIRING; CLINICAL ARTICLE; CONVULSION; DRUG METABOLISM; EXON; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPAN; PEDIGREE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE;

AMINO ACID SEQUENCE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JAPAN; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; PEDIGREE; POLYMORPHISM, GENETIC; SEQUENCE ALIGNMENT;

EID: 0028044085     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kupfer, A., and R. Preisig. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26:753-759 (1984).
2. Wedlund, P. J., W. S. Aslanian, C. B. McAllister, G. R. Wilkinson, and R. A. Branch. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug polymorphism. Clin. Pharmacol. Ther. 36:773-780 (1984).
3. Wilkinson, G. R., F. P. Guengerich, and R. A. Branch. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43:53-76 (1989).
4. Ward, S. A., F. Goto, K. Nakamura, E. Jacqz, G. R. Wilkinson, and R. A. Branch. S-Mephenytoin 4'-hydroxylase is inherited as an autosomal-recessive trait in Japanese families. Clin. Pharmacol. Ther. 42:96-99 (1987).
5. Inaba, T., M. Jurima, and W. Kalow. Family studies of mephenytoin hydroxylation deficiency. Am. J. Hum. Genet. 38:768-772 (1986).
6. Nakamura, K., F. Goto, W. A. Ray, C. B. McAllister, E. Jacqz, G. R. Wilkinson, and R. A. Branch. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38:402-408 (1985).
7. Goldstein, J. A., M. B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy, J. M. Lasker, and B. I. Ghanayem. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 33:1743-1752 (1994).
8. Wrighton, S. A., J. C. Stevens, G. W. Becker, and M. VandenBranden. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch. Biochem. Biophys. 306:240-245 (1993).
9. Adedoyin, A., C. Prakash, D. O'Shea, I. A. Blair, and G. R. Wilkinson. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 4:27-38 (1994).
10. Kupfer, A., and R. A. Branch. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin. Pharmacol. Ther. 38:414-418 (1985).
11. Andersson, T., C.-G. Regardh, Y.-C. Lou, Y. Zhang, M. L. Dahl, and L. Bertilsson. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2:25-31 (1992).
12. Ward, S. A., N. A. Helsby, E. Skejlbo, K. BrØsen, L. F. Gram, and A. M. Breckenridge. The activation of the biguanide antimalarial proguanil cosegregates with the mephenytoin oxidation polymorphism: a panel study. Br. J. Clin. Pharmacol. 31:689-692 (1991).
13. Sindrup, S. H., K. BrØsen, M. G. J. Hansen, T. Aaes-Jorgensen, K. F. Overo, and L. F. Gram. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monit. 13:11-17 (1993).
14. Ward, S. A., T. Walle, U. K. Walle, G. R. Wilkinson, and R. A. Branch. Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin. Pharmacol. Ther. 45:72-79 (1989).
15. Baumann, P., M. Jonzier-Perez, L. Kerb, A. Kupfer, D. Tingueley, and J. Schöpf. Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int. Clin. Psychopharmacol. 1:102-112 (1986).
16. Nielsen, K. K., K. BrØsen, J. Hansen, and L. F. Gram. Single-dose kinetics of clomipramine: relationship to the sparteine/debrisoquine and S-mephenytoin oxidation polymorphisms. Clin. Pharmacol Ther. 55:518-527 (1994).
17. Skjelbo, E., K. BrØsen, J. Hallas, and L. F. Gram. The mephenytoin oxidative polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49:18-23 (1991).
18. Bertilsson, L., T. K. Henthorn, E. Sanz, G. Tybring, J. Säwe, and T. Villén. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. Clin. Pharmacol. Ther. 45:348-355 (1989).
19. de Morais, S. M. F., G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J. Biol. Chem. 269:15419-15422 (1994).
20. Sambrook, J., E. F. Fritsch, and T. Maniatis. Molecular Cloning: A Laboratory Manual, Ed. 2. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 9.16-9.18 (1989).
21. Romkes, M., M. B. Faletto, J. A. Blaisdell, J. L. Raucy, and J. A. Goldstein. Cloning and expression of complementary DNAs for multiple members of the human P450IIC subfamily. Biochemistry 30:3247-3255 (1991).
22. de Morais, S. M. F., H. Schweikl, J. Blaisdell, and J. A. Goldstein. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem. Biophys. Res. Commun. 194:194-201 (1993).